使用肠道器官及其细胞外囊泡的组合疗法用于与骨质疏松症复杂的炎症性肠道疾病
Mingkai Wang1,2,3,4, Ruiyang Li5, Shihao Sheng5
1Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Journal of orthopaedic translation
|June 17, 2025
概括
肠道器官及其细胞外囊泡为炎症性肠病 (IBD) 和骨质疏松症提供了一种新的双重治疗方法. 这种方法可以缓解肠道炎症并逆转骨质损失,显示出治疗这种常见的并发症的希望.
科学领域:
- 胃肠道学和再生医学
- 骨生物学和疾病
- 生物技术和治疗学
背景情况:
- 炎症性肠病 (IBD) 经常与骨质疏松症 (OP) 发生并发,在有限的治疗选择下,具有重大临床挑战.
- 肠道器官 (IOs) 具有再生能力,从中衍生出的细胞外囊泡 (IOEVs) 可以调节肠道炎症.
- IOEV含有特定的微RNA (miRNA),具有潜在的抗炎和骨质效应.
研究的目的:
- 研究肠道有机体 (IOs) 及其细胞外囊泡 (IOEVs) 的治疗潜力,用于治疗并发性炎症性肠病 (IBD) 和骨质疏松症 (OP).
- 在IBD相关骨质疏松症的临床前模型中评估IO和IOEV在改善肠道炎症和逆转骨质损失方面的疗效.
主要方法:
- 建立3D肠道有机体 (IOs) 并分离它们的细胞外囊泡 (IOEVs).
- IOEVs的miRNA测序以确定潜在的治疗分子.
- 使用脂聚糖化物 (LPS) 的IBD体外建模以及在硫酸 (DSS) 诱导的IBD小鼠模型中的体内评估.
- 评估肠道屏障完整性,细胞亡/增殖,细胞因子概况和骨参数.
主要成果:
- 在体外,IO和IOEV减少了细胞死亡和细胞亡.
- 在体内,在DSS诱导的IBD小鼠中,治疗恢复了体重,改善了结肠形态和正常化了组织结构.
- 治疗增强了粘膜屏障完整性 (ZO-1,Ki67上调;Caspase-3下调) 和调节的炎症细胞因子 (TNF-α,IL-1β,IL-6下调;IL-10上调).
- 重要的是,IO和IOEV联合治疗在IBD模型中逆转了骨质疏松症的进展,改善了骨质和骨质量.
结论:
- 肠道器官及其细胞外囊泡代表了IBD相关骨质疏松症的新型双作用生物疗法.
- 这种来自器官的生物方法调节肠骨轴,为管理这种复杂的并发症提供了一个有希望的策略.
- 在IOEV中的功能性miRNAs支持其作为系统性炎症并发症的无细胞治疗方法的发展.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
432
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
432
Drugs for Treatment of Diarrhea-Predominant IBS
315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315


